GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » Cyclically Adjusted PS Ratio

ChromaDex (ChromaDex) Cyclically Adjusted PS Ratio : 4.05 (As of Apr. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is ChromaDex Cyclically Adjusted PS Ratio?

As of today (2024-04-29), ChromaDex's current share price is $3.56. ChromaDex's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.88. ChromaDex's Cyclically Adjusted PS Ratio for today is 4.05.

The historical rank and industry rank for ChromaDex's Cyclically Adjusted PS Ratio or its related term are showing as below:

CDXC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.5   Med: 7.12   Max: 24.02
Current: 3.93

During the past years, ChromaDex's highest Cyclically Adjusted PS Ratio was 24.02. The lowest was 1.50. And the median was 7.12.

CDXC's Cyclically Adjusted PS Ratio is ranked better than
57.31% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs CDXC: 3.93

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ChromaDex's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.282. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.88 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ChromaDex Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ChromaDex's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Cyclically Adjusted PS Ratio Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.05 8.30 5.53 2.16 1.63

ChromaDex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 1.88 1.88 1.70 1.63

Competitive Comparison of ChromaDex's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, ChromaDex's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChromaDex's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ChromaDex's Cyclically Adjusted PS Ratio falls into.



ChromaDex Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ChromaDex's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.56/0.88
=4.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChromaDex's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ChromaDex's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.282/129.4194*129.4194
=0.282

Current CPI (Dec. 2023) = 129.4194.

ChromaDex Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.087 99.695 0.113
201406 0.109 100.560 0.140
201409 0.116 100.428 0.149
201412 0.119 99.070 0.155
201503 0.147 99.621 0.191
201506 0.170 100.684 0.219
201509 0.176 100.392 0.227
201512 0.006 99.792 0.008
201603 0.196 100.470 0.252
201606 0.239 101.688 0.304
201609 0.104 101.861 0.132
201612 0.117 101.863 0.149
201703 0.089 102.862 0.112
201706 0.100 103.349 0.125
201709 0.128 104.136 0.159
201712 0.147 104.011 0.183
201803 0.120 105.290 0.148
201806 0.142 106.317 0.173
201809 0.147 106.507 0.179
201812 0.164 105.998 0.200
201903 0.182 107.251 0.220
201906 0.200 108.070 0.240
201909 0.209 108.329 0.250
201912 0.219 108.420 0.261
202003 0.240 108.902 0.285
202006 0.251 108.767 0.299
202009 0.230 109.815 0.271
202012 0.250 109.897 0.294
202103 0.229 111.754 0.265
202106 0.260 114.631 0.294
202109 0.254 115.734 0.284
202112 0.260 117.630 0.286
202203 0.253 121.301 0.270
202206 0.245 125.017 0.254
202209 0.250 125.227 0.258
202212 0.284 125.222 0.294
202303 0.302 127.348 0.307
202306 0.271 128.729 0.272
202309 0.260 129.860 0.259
202312 0.282 129.419 0.282

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ChromaDex  (NAS:CDXC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ChromaDex Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ChromaDex's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Industry
Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus

ChromaDex Named Brianna Gerber Chief Financial Officer

By Business Wire Business Wire 01-05-2023